Spots Global Cancer Trial Database for assay
Every month we try and update this database with for assay cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Predictive Assays In Cervix Cancer | NCT01181375 | Cervical Cancer | Tumour Biopsies... | 18 Years - | University Health Network, Toronto | |
| ChemoFx® PRO - A Post-Market Data Collection Study | NCT00669422 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Neoplas... Endometrial Can... Vaginal Cancer Vulvar Cancer Cervical Cancer | 18 Years - | Precision Therapeutics | ||
| Predictive Assays In Cervix Cancer | NCT01181375 | Cervical Cancer | Tumour Biopsies... | 18 Years - | University Health Network, Toronto | |
| 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | NCT00841035 | Pancreatic Canc... | erlotinib | 19 Years - 80 Years | University of Alabama at Birmingham | |
| Test Semiquantitative Prostate Specific Antigen (PSA) | NCT00853710 | Prostate Cancer Prostatic Neopl... Prostatic Disea... | PSA assay | 18 Years - | Institut Curie | |
| Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo) | NCT02137811 | Cancer | MICK Assay | - | Pierian Biosciences | |
| A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study | NCT01271959 | Solid Organ Tum... | 18 Years - | Precision Therapeutics | ||
| MElanoma Research Lymph Node Prediction Implementation National_001 | NCT04759781 | Melanoma | 18 Years - | SkylineDx | ||
| ChemoFx® PRO - A Post-Market Data Collection Study | NCT00669422 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Neoplas... Endometrial Can... Vaginal Cancer Vulvar Cancer Cervical Cancer | 18 Years - | Precision Therapeutics | ||
| Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo) | NCT02137811 | Cancer | MICK Assay | - | Pierian Biosciences | |
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00288275 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | 18 Years - | Precision Therapeutics | ||
| ChemoFx® PRO - A Post-Market Data Collection Study | NCT00669422 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Neoplas... Endometrial Can... Vaginal Cancer Vulvar Cancer Cervical Cancer | 18 Years - | Precision Therapeutics | ||
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00288275 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | 18 Years - | Precision Therapeutics | ||
| 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | NCT00841035 | Pancreatic Canc... | erlotinib | 19 Years - 80 Years | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
